Shareholders of Abbott Laboratories have taken decisive action to shape the company’s future trajectory. Despite a stock price that remains under pressure over a one-year horizon, recent corporate developments signal a clear commitment to expansion and shareholder returns. The medical technology giant is moving forward with a major acquisition and a confirmed dividend, underscoring its strategic priorities.
Dividend Consistency and Strategic Acquisition
Abbott continues its long-standing tradition of rewarding shareholders, announcing a quarterly dividend of $0.63 per share. This translates to an annualized payout of $2.52 and marks the 54th consecutive year of dividend increases. The dividend is scheduled for payment on May 15, with April 15 set as the record date.
Simultaneously, the company has received overwhelming shareholder support for its planned expansion. In a definitive vote, over 99% of the votes cast were in favor of acquiring Exact Sciences Corporation. Market experts view this strategic acquisition as a significant move to broaden Abbott’s footprint within the healthcare sector.
Financial Outlook and Key Growth Drivers
Supporting these actions is a robust financial forecast for the ongoing 2026 fiscal year. Management anticipates organic sales growth in the range of 6.5% to 7.5%. Adjusted earnings per share (EPS) are projected to land between $5.55 and $5.80.
Should investors sell immediately? Or is it worth buying Abbott Laboratories?
A primary engine for this growth is Abbott’s medical devices division. This segment already demonstrated strong momentum, posting a 10.5% sales increase in the fourth quarter of 2025. A major contributor was the continuous glucose monitoring (CGM) product line. Looking ahead to 2026, company leadership expects this specific diabetes care business to deliver further growth in the low double-digit percentage range.
Market Context and Insider Activity
These fundamental developments unfold against a backdrop of recent share price weakness. The equity currently trades around €95, reflecting a decline of nearly 24% over the past twelve months. The completion of the Exact Sciences deal is now seen as a potential catalyst to rebuild investor confidence and counter this trend.
In parallel, minor insider transactions were disclosed in early March. Executives including Elizabeth C. Cushman and John Jr. McCoy sold small parcels of shares. Given the relatively limited volume involved, these sales are unlikely to carry significant weight when contrasted with the company’s large-scale strategic initiatives.
With the strategic acquisition moving forward and a stable growth outlook for its core diabetes care business, investor attention is now focused on whether these operational strengths can provide a durable foundation for the stock’s recovery.
Ad
Abbott Laboratories Stock: Buy or Sell?! New Abbott Laboratories Analysis from March 6 delivers the answer:
The latest Abbott Laboratories figures speak for themselves: Urgent action needed for Abbott Laboratories investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 6.
Abbott Laboratories: Buy or sell? Read more here...
